Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
49 participants
OBSERVATIONAL
2023-09-19
2024-04-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
NCT05416060
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
NCT06931275
PROmoting Diabetes Education and Management Through Peer Support and Team Referral
NCT05587348
Remotely Delivered Mindfulness-Based Diabetes Education
NCT06312553
Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes
NCT03130699
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AID Group
We anticipate enrolling between 30 and 50 participants who will be recruited to participate in the Automated Insulin Delivery (AID) system study.
No interventions assigned to this group
MDI + CGM Group
We anticipate that between 10 and 30 participants will be enrolled in the study and will be utilizing Multiple Daily Injections (MDI) therapy in conjunction with Continuous Glucose Monitoring (CGM). MDI therapy will be defined as administering three or more injections per day.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years and above
* Use of a CGM
* Use of an insulin pump or on MDI
* Access to the Internet and e-mail
* Access to a smartphone with photographic capability
* Able and willing to provide informed consent
* Any condition which, in the opinion of an investigator, would make the subject not qualified to participate in the study.
* Adults unable to consent
* Adults unable to speak English
* Individuals who are not yet adults (infants, children, teenagers)
* Pregnant women
* Prisoners
* Cognitively impaired adults
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Diabetes Technology Society
OTHER
Florida State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jing Wang
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jing Wang, PhD
Role: PRINCIPAL_INVESTIGATOR
Dean & Prof. of FSU College of Nursing
David C Klonoff, MD
Role: PRINCIPAL_INVESTIGATOR
President of Diabetes Technology Society and Clinical Professor of UCSF Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Diabetes Technology Society
Burlingame, California, United States
Florida State University
Tallahassee, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00004453
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.